Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 6

1.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al.

Nature. 1993 Jun 3;363(6428):458-60.

PMID:
8099202
2.
3.

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG.

Cancer Res. 1996 Mar 15;56(6):1241-3.

4.

Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a.

Heizmann O, Haecker FM, Zumsteg U, Müller B, Oberholzer M, Oertli D.

Eur J Surg Oncol. 2006 Feb;32(1):98-102. Epub 2005 Dec 1.

PMID:
16325365
5.

Pheochromocytoma penetrance varies by RET mutation in MEN 2A.

Quayle FJ, Fialkowski EA, Benveniste R, Moley JF.

Surgery. 2007 Dec;142(6):800-5; discussion 805.e1. Epub 2007 Nov 5. Erratum in: Surgery. 2008 Feb;143(2):301.

PMID:
18063059
6.

Familial prevalence and age of RET germline mutations: implications for screening.

Machens A, Dralle H.

Clin Endocrinol (Oxf). 2008 Jul;69(1):81-7. Epub 2008 Jul 1.

PMID:
18062802

Supplemental Content

Support Center